Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19,The Journal of Clinical Investigation

当前位置： X-MOL 学术 › J. Clin. Invest. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2021 , DOI: 10.1172/jci151788
Shanna A Arnold Egloff _{1,

2} , Angela Junglen _{1,

2,

3} , Joseph Sa Restivo ₂ , Marjorie Wongskhaluang ₂ , Casey Martin _{1,

2,

3} , Pratik Doshi _{1,

2,

3} , Daniel Schlauch _{1,

3} , Gregg Fromell _{1,

2} , Lindsay E Sears _{1,

2} , Mick Correll _{1,

3} , Howard A Burris _{1,

2} , Charles F LeMaistre _{1,

2}

Affiliation

BACKGROUND. Evidence supporting convalescent plasma (CP), one of the first investigational treatments for coronavirus disease 2019 (COVID-19), has been inconclusive, leading to conflicting recommendations. The primary objective was to perform a comparative effectiveness study of CP for all-cause, in-hospital mortality in patients with COVID-19.

中文翻译：

恢复期血浆与 COVID-19 住院患者的死亡率降低和临床轨迹改善有关

背景。支持恢复期血浆 (CP) 是 2019 年冠状病毒病 (COVID-19) 的首批研究性治疗方法之一的证据尚无定论，导致建议相互矛盾。主要目的是对 CP 对 COVID-19 患者的全因住院死亡率进行比较有效性研究。

更新日期：2021-10-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文